einstein (São Paulo). 29/May/2020;18:eAE5793.

Intensive support recommendations for critically-ill patients with suspected or confirmed COVID-19 infection

Thiago Domingos Corrêa ORCID logo , Gustavo Faissol Janot de Matos ORCID logo , Bruno de Arruda Bravim ORCID logo , Ricardo Luiz Cordioli ORCID logo , Alejandra del Pilar Gallardo Garrido ORCID logo , Murillo Santucci Cesar de Assuncao ORCID logo , Carmen Silvia Valente Barbas ORCID logo , Karina Tavares Timenetsky ORCID logo , Roseny dos Reis Rodrigues ORCID logo , Hélio Penna Guimarães ORCID logo , Roberto Rabello Filho ORCID logo , Frederico Polito Lomar ORCID logo , Farah Christina de La Cruz Scarin ORCID logo , Carla Luciana Batista ORCID logo , Adriano José Pereira ORCID logo , João Carlos de Campos Guerra ORCID logo , Bárbara Vieira Carneiro, Ricardo Kenji Nawa ORCID logo , Rodrigo Martins Brandão ORCID logo , Antônio Eduardo Pereira Pesaro ORCID logo , Moacyr Silva Júnior ORCID logo , Fabricio Rodrigues Torres de Carvalho ORCID logo , Cilene Saghabi de Medeiros Silva ORCID logo , Ana Claudia Ferraz de Almeida ORCID logo , Marcelo Franken ORCID logo , Marcele Liliane Pesavento ORCID logo , Raquel Afonso Caserta Eid ORCID logo , Leonardo José Rolim Ferraz ORCID logo

DOI: 10.31744/einstein_journal/2020AE5793

ABSTRACT

In December 2019, a series of patients with severe pneumonia were identified in Wuhan, Hubei province, China, who progressed to severe acute respiratory syndrome and acute respiratory distress syndrome. Subsequently, COVID-19 was attributed to a new betacoronavirus, the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Approximately 20% of patients diagnosed as COVID-19 develop severe forms of the disease, including acute hypoxemic respiratory failure, severe acute respiratory syndrome, acute respiratory distress syndrome and acute renal failure and require intensive care. There is no randomized controlled clinical trial addressing potential therapies for patients with confirmed COVID-19 infection at the time of publishing these treatment recommendations. Therefore, these recommendations are based predominantly on the opinion of experts (level C of recommendation).

Intensive support recommendations for critically-ill patients with suspected or confirmed COVID-19 infection